Detalhe da pesquisa
1.
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).
Radiother Oncol
; 196: 110294, 2024 Apr 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38653380
2.
Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate.
Cancers (Basel)
; 15(7)2023 Mar 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37046627
3.
Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Radiother Oncol
; 185: 109728, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37301259
4.
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC.
Cancers (Basel)
; 14(3)2022 Jan 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35158841
5.
Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
Breast Cancer
; 29(2): 274-286, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-34865205
6.
Carbon Monoxide Diffusing Capacity (DLCO) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III.
Diagnostics (Basel)
; 12(5)2022 Apr 19.
Artigo
Inglês
| MEDLINE | ID: mdl-35626183